Skip to main content
OpenTrials
Completed

NCT Number: NCT07219316

Regenerative Collagen Scaffold for Breast Volume Restoration After Breast Cancer Excision

This clinical trial evaluates the safety and efficacy of High Purity Type I Collagen scaffold for breast volume restoration following breast-conserving surgery (BCS). The regenerative collagen matrix serves as a biocompatible scaffold promoting tissue ingrowth, neovascularization, and gradual remodeling, thereby improving cosmetic outcomes and patient quality of life after partial mastectomy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Adichunchanagiri Institute of Medical Sciences, Mandya, Karnataka, India

Loading trial locations.

About this study

Breast-conserving surgery (BCS) is the standard treatment for early-stage breast cancer, balancing oncological safety with aesthetic preservation. However, postoperative volume defects may cause breast asymmetry and psychological distress. Traditional options such as flaps or implants are limited by donor-site morbidity and complications.

This prospective, single-arm, bi-centre study investigates the clinical performance of a high-purity, cross-linked bovine Type I collagen scaffold for immediate breast volume restoration. The study will assess safety, volume maintenance, cosmetic appearance, and patient-reported outcomes through standardized 3D imaging, MRI analysis, and validated quality-of-life instruments.

The study will enroll 40 women undergoing BCS with expected volume defects ≥20%, with 2-month postoperative follow-up for primary endpoints.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female, 18-70 years
  • Histologically confirmed breast carcinoma (Stage 0-II) or high-risk lesions requiring excision
  • Expected postoperative defect ≥20% of total breast volume
  • ECOG 0-1, adequate organ function
  • Informed consent provided, compliant with follow-up schedule

Exclusion criteria

  • Prior breast surgery or radiotherapy to affected breast
  • Locally advanced or inflammatory carcinoma
  • Collagen hypersensitivity or autoimmune disease
  • Active infection, pregnancy, lactation, or smoking within 6 weeks
  • Concurrent participation in other clinical studies

Treatment and study plan

High Purity Type I Collagen Scaffold (Regenerative Matrix)

Device

Standard breast-conserving surgery followed by immediate scaffold placement into the excision cavity. The scaffold is sutured using absorbable sutures and covered with standard wound closure. Postoperative care follows institutional protocols. Adjuvant radiotherapy and chemotherapy as indicated per oncological protocols; standard antibiotics and analgesics.

Primary outcomes

  1. Volume Restoration

    Time frame: 2 months post-operative

    Proportion of patients achieving ≥80% breast volume retention at 2 months assessed by imaging/MRI

  2. Patient Satisfaction With Breast Volume Restoration

    Time frame: 4 weeks and 8 weeks post-operative

    Patient satisfaction ≥7/10 on standardized satisfaction scale (BREAST-Q). The BREAST-Q is a validated patient-reported outcome measure (PROM) used to assess the quality of life and satisfaction of patients undergoing breast surgery. It consists of specific modules for different procedures, like reconstruction, and measures aspects such as psychological well-being, physical well-being (chest and sexual), and satisfaction with the breasts and care. The scale, which results in scores from 0 to 100, helps evaluate the impact of surgery from the patient's perspective. Scores range from 0 to 100, with higher scores indicating a greater degree of health-related quality of life or satisfaction.

Secondary outcomes

  1. Objective Volume Assessment

    Time frame: 2 weeks, 4 weeks, and 8 weeks post-operative

    Percentage change in breast volume at 2, 4, and 8 weeks post-surgery

  2. Cosmetic Assessment

    Time frame: 2 months post-operative

    Physician-rated 4-point cosmetic score. This is a standardized visual assessment tool used to evaluate the aesthetic outcome of the operated breast compared to the contralateral breast. The assessment is based on parameters such as breast shape, volume, symmetry, contour, nipple-areolar complex position, and scar appearance. The 4-point grading system is typically defined as:

    Grade 4 - Excellent - Described as operated breast almost identical to contralateral side - Criteria is minimal asymmetry, natural contour Grade 3 - Good - Described as slight difference in shape or volume - Acceptable symmetry and cosmetic result Grade 2 - Fair - Described as noticeable asymmetry or distortion - Moderate contour irregularity or scar visibility Grade 1 - Poor - Described as significant deformity or volume loss - Unacceptable cosmetic result

  3. Radiological Outcomes

    Time frame: Immediate postoperative, 4 weeks, and 8 weeks

    MRI Scoring System - Scaffold Integration, Vascularization & Resorption:

    Standardized MRI assessment of scaffold performance (integration, neovascularization, resorption) at baseline, Week 4, and Week 8.

    MRI protocol:

    T1 (axial/sagittal), T2/STIR (axial), DCE T1 (pre-contrast, early 30-60 s, intermediate 90-120 s, delayed 4-6 min),

    Scores (0-3 each):

    A. Integration: 0 = none; 1 = minimal; 2 = moderate; 3 = complete tissue continuity.

    B. Vascularization: 0 = none; 1 = mild/delayed; 2 = moderate (neovascular); 3 = marked (early enhancement).

    C. Resorption: 0 > 75% residual; 1 = 50-75%; 2 = 25-50%; 3 < 25% residual. D. Tissue Quality: 0 = fluid-filled; 1 = mostly fluid; 2 = mixed; 3 = tissue-like.

    Composite MRI Integration Score (MIS 0-12): Higher = better integration/remodeling.

    Interpretation:

    0-3 Poor, 4-7 Moderate, 8-10 Good, 11-12 Excellent.

  4. Number of Participants With Postoperative Complications

    Time frame: 2 months

    Number of participants experiencing postoperative complications within the 2-month follow-up period after breast cancer excision and collagen scaffold implantation. Complications assessed include seroma, hematoma, surgical site infection, abscess, wound dehiscence, scaffold exposure or extrusion, prolonged postoperative pain, and ecchymosis.

    Each participant is counted once per complication category. Higher values indicate greater frequency of complications.

Sponsors and collaborators

Lead sponsor

Adichunchanagiri Institute of Medical Sciences, B G Nagara

Other

Registry information

Official study title

Regenerative High Purity Type I Collagen Scaffold for Breast Cancer Excision Repair and Reconstruction: A Prospective Multicenter Clinical Trial

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Oct 21, 2025
Registry last updated
Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.